Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital

Journal of Child Neurology

Volumn 21, Issue 1, 2006, Pages 48-53

  Castro Gago, Manuel ^a   Novo Rodríguez, María Inés ^a   Blanco Barca, Manuel Oscar ^a   Urisarri Ruíz de Cortázar, Adela ^a   Rodríguez García, Javier ^a   Rodríguez Segade, Santiago ^a   Eirís Puñal, Jesús ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHENOBARBITAL; TRIACYLGLYCEROL; VALPROIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ARTICLE; BENIGN CHILDHOOD EPILEPSY; BLOOD SAMPLING; CHILD; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; FOOD DRUG INTERACTION; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADOLESCENT; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; DIET; EPILEPSY; FEMALE; HUMANS; LIPIDS; LIPOPROTEIN(A); MALE; PHENOBARBITAL; TIME FACTORS; VALPROIC ACID;

EID: 33646895142     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738060210011601     Document Type: Article

References (45)

1. Newman WP, Freedman DS, Voors AW: Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: The Bogalusa Heart Study. N Engl J Med 1986;314:138-144.
2. Berenson GS, Srinivasan SR, Nicklas TA, Webber LS: Cardiovascular risk factors in children and early prevention of heart disease. Clin Chem 1988;34:B114-B122.
3. Pelkonen R, Fogelholm R, Nikkilä EA: Increase in serum cholesterol during phenytoin treatment. BMJ 1975;283:85.
4. Nikkilä EA, Kaste M, Ehnholm C, Viikari J: Elevation of high-density lipoprotein in epileptic patients treated with phenytoin. Acta Med Scand 1978;204:517-520.
5. Durrington PN: Effects of phenobarbitone on plasma apolipoprotein B and plasma high-density lipoprotein cholesterol. Clin Sci 1979;56:501-504.
6. Luoma PV, Reunanen MI, Sotaniemi EA: Changes in serum triglycerides and cholesterol levels during long term phenytoin treatment for epilepsy. Acta Med Scand 1979;206:229-231.
7. Luoma PV, Vilho V, Myllylä VV, et al: Plasma high density lipoprotein cholesterol in epileptics treated with various anticonvulsants. Eur Neurol 1980;19:67-72.
8. Luoma PV, Myllylä VV, Hokkanen E: Relationship between plasma high-density lipoprotein cholesterol and anticonvulsant levels in epileptics. J Cardiovasc Pharmacol 1982;4:1024-1027.
9. O'Neill B, Callaghan N, Stapleton M, Nolloy W: Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients taking carbamazepine or phenytoin. Acta Neurol Scand 1982; 65:104-109.
10. Heldemberg D, Harel S, Holtzman M, et al: The effect of chronic anticonvulsant therapy on serum lipids and lipoproteins in epileptic children. Neurology 1983;33:510-513.
11. Perucca E, Hedges A, Makki KA, et al: A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-410.
12. Reddy MN: Effect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein, cholesterol, and apolipoproteins A and B in children with epilepsy. Proc Soc Exp Biol Med 1985;180:359-363.
13. Calandre EP, Rodríguez-López C, Blazquez A, Cano D: Serum lipids, lipoprotein and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand 1991;83:250-253.
14. Brown DW, Ketter TA, Crumlish J, Post RM: Carbamazepine-induced increase in total serum cholesterol: Clinical and theoretical implications. J Clin Psychopharmacol 1992;12:431-437.
15. Franzoni E, Govoni M, D'Addato S, et al: Total cholesterol, high-density lipoprotein cholesterol and triglycerides in children receiving antiepileptic drugs. Epilepsia 1992;33:932-935.
16. Isojärvi JIT, Pakarinen AJ, Myllylä VV: Serum lipid levels during carbamazepine medication. A prospective study. Arch Neurol 1993;50:590-593.
17. Zeitlhofer J, Doppelbauer A, Tribl G, et al: Changes of serum lipid patterns during long-term anticonvulsive treatment. Clin Invest 1993;71:574-578.
18. Eirís JM, Lojo S, Del Río MC, et al: Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995;45:1155-1157.
19. Eirís J, Novo-Rodríguez MI, Del Río M, et al: The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res 2000;41:1-7.
20. De Juan J, Crespo M, Braga S: Efectos del fenobarbital, ácido valproico y carbamacepina sobre lípidos y lipoproteínas séricas en población infanto-juvenil. An Esp Pediatr 1996; 44:133-138.
21. Sözuer DT, Atakli D, Dogu O, et al: Serum lipids in epileptic children treated with carbamazepine and valproate. Eur J Pediatr 1997;156:565-567.
22. Yalçin E, Hassanzadeh A, Mawlud K: The effects of long-term anticonvulsive treatment on serum lipid profile. Acta Paediatr Jpn 1997;39:342-345.
23. Verrotti A, Domizio S, Angelozzi B, et al: Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health 1997;33:242-245.
24. Verrotti A, Basciani F, Domizio S, et al: Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol 1998;19:364-367.
25. Sudhop T, Bauer J, Elger CE, Von Bergmann K: Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: A gender-related study. Epilepsia 1999;40:480-484.
26. Demircioglu S, Soylu A, Dirik E: Carbamazepine and valproic acid: Effects on the serum lipids and liver functions in children. Pediatr Neurol 2000;23:142-146.
27. Kaste M, Muuronen A, Nikkilä EA, Neuvonen PJ: Increase of low serum concentrations of high density lipoprotein (HDL) cholesterol in TIA patients. Stroke 1983;14:525-530.
28. Muuronen A, Kaste M, Nikkilä EA, Tolppanen EM: Mortality from ischaemic heart disease among patients using anticonvulsive drugs; a case-control study. BMJ 1985;291:1481-1483.
29. Annegers JF, Hauser WA, Shirts SB: Heart disease mortality and morbidity in patients with epilepsy. Epilepsia 1984;25:699-704.
30. Schwaninger M, Ringleb P, Anneceke A, et al: Elevated plasma concentrations of lipoprotein (a) in medicated epileptic patients. J Neurol 2000;247:687-690.
31. Aynaci FM, Orhan F, Örem A, et al: Effect of antiepileptic drugs on plasma lipoprotein (a) and other lipid levels in childhood. J Child Neurol 2001;16:367-369.
32. Brämswig S, Sudhop T, Luers C, et al: Lipoprotein (a) concentration increases during treatment with carbamazepine. Epilepsia 2003;44:457-460.
33. National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992;89(Suppl):525-583.
34. Contois JH, Gillmor RG, Moore RE, et al: Quantitative determination of cholesterol in lipoprotein fractions by electrophoresis. Clin Chim Acta 1999;282:1-14.
35. Berg K: A new serum type system in man - The Lp system. Acta Pathol Microbiol Scand 1963;59:369-382.
36. Kark JD, Sandholzer C, Friedlander Y, Utermann G: Plasma Lp(a), apolipoprotein (a) isoforms and acute myocardial infarction in men and women: A case-control study in the Jerusalem population. Atherosclerosis 1993;98:139-151.
37. Van Biervliet JP, Labeur M, Michiels G, et al: Lipoprotein (a) profiles and evaluation in newborns. Atherosclerosis 1991;86:173-181.
38. Wang XL, Wilcken DEL, Dudman NP: Early expression of the apolipoprotein (a) gene: Relationships between infants' and their parents' serum apolipoprotein (a) levels. Pediatrics 1992;89: 401-406.
39. Örem A, Deger O, Önder E, et al: Distribution of serum lipoprotein (a) concentrations in a healthy Turkish population. Ann Clin Biochem 1994;31:343-346.
40. Tomlinson JE, McLean JW, Lawn RM: Rhesus monkey apolipoprotein (a): Sequence, evolution, and sites of synthesis. J Biol Chem 1989;264:5957-5965.
41. Luoma PV, Sotaniemi EA, Pelkonen RO, et al: Induction and lipoproteins. Lancet 1982;1:625.
42. Luoma PV, Sotaniemi EA, Arranto AJ: Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetcis. Scand J Clin Lab Invest 1983;43:671-675.
43. Luoma PV: Microsomal enzyme induction, lipoproteins and atherosclerosis. Pharmacol Toxicol 1988;62:243-249.
44. Horie A, Suga T: Enhacement of peroxisomal beta-oxidation in the liver of rats and mice treated with valproic acid. Biochem Pharmacol 1985;34:1357-1362.
45. American Academy of Pediatrics, Committee on Nutrition, 1998: Cholesterol in childhood. Pediatrics 1998;101:141-147.